These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 766908)

  • 1. Spironolactone in essential hypertension: evidence against its effect through mineralocorticoid antagonism.
    Hoffbrand BI; Edmonds CJ; Smith T
    Br Med J; 1976 Mar; 1(6011):682-4. PubMed ID: 766908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of aspirin to antagonize the antihypertensive effect of spironolactone in low-renin hypertension.
    Hollifield JW
    South Med J; 1976 Aug; 69(8):1034-6. PubMed ID: 785608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination.
    Douglas JG; Hollifield JW; Liddle GW
    JAMA; 1974 Feb; 227(5):518-21. PubMed ID: 4589187
    [No Abstract]   [Full Text] [Related]  

  • 4. Diuretic therapies in low renin and normal renin essential hypertension.
    Brooks CS; Johnson CA; Kotchen JM; Kotchen TA
    Clin Pharmacol Ther; 1977 Jul; 22(1):14-20. PubMed ID: 326459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin.
    Brown JJ; Davies DL; Ferriss JB; Fraser R; Haywood E; Lever AF; Robertson JI
    Br Med J; 1972 Jun; 2(5816):729-34. PubMed ID: 4338668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium and the renin-angiotensin system in essential hypertension and mineralocorticoid excess.
    Lebel M; Schalekamp MA; Beevers DG; Brown JJ; Davies DL; Fraser R; Kremer D; Lever AF; Morton JJ; Robertson JI; Tree M; Wilson A
    Lancet; 1974 Aug; 2(7876):308-9. PubMed ID: 4136047
    [No Abstract]   [Full Text] [Related]  

  • 7. [Correlations between blood pressure, blood volume and plasma renin during therapy with diuretics in essential hypertension. Comparison between the mineralocorticoid antagonist spironolactone and the "loop" diuretic mefruside].
    Beretta-Piccoli C; Weidmann P; de Châtel R; Hirsch D; Reubi FC
    Schweiz Med Wochenschr; 1977 Jan; 107(4):104-15. PubMed ID: 834983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension.
    Solheim SB; Sundsfjord JA; Giezendanner L
    Acta Med Scand; 1975 Jun; 197(6):451-6. PubMed ID: 1098396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on essential hypertension with suppressed plasma renin activity: sodium excretion pattern on salt restriction and effects of spironolactone on blood pressure and plasma renin activity.
    Uchida K; Morimoto S; Takeda R; Murakami M
    Jpn Circ J; 1972 Dec; 36(12):1301-11. PubMed ID: 4679217
    [No Abstract]   [Full Text] [Related]  

  • 10. Spironolactone and amiloride in hypertensive patients with and without aldosterone excess.
    Hoefnagels WH; Drayer JI; Smals AG; Kloppenborg PW
    Clin Pharmacol Ther; 1980 Mar; 27(3):317-23. PubMed ID: 6987022
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans.
    Williamson PM; Kelly JJ; Whitworth JA
    J Hypertens Suppl; 1996 Dec; 14(5):S37-41. PubMed ID: 9120683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess.
    Spark RF; Melby JC
    Ann Intern Med; 1971 Dec; 75(6):831-6. PubMed ID: 5134893
    [No Abstract]   [Full Text] [Related]  

  • 13. [Exchangeable sodium, total-body potassium, plasma volume, and hypotensive effect of various diuretics in patients with essential hypertension and low plasma renin level (author's transl)].
    Distler A; Keim HJ; Philipp T; Philippi A; Walter U; Werner E
    Dtsch Med Wochenschr; 1974 Apr; 99(17):864-9. PubMed ID: 4834874
    [No Abstract]   [Full Text] [Related]  

  • 14. Similar effects of hydrochlorothiazide and spironolactone on plasma renin activity in essential hypertension.
    Acchiardo S; Dustan HP; Tarazi RC
    Cleve Clin Q; 1972; 39(4):153-62. PubMed ID: 4660197
    [No Abstract]   [Full Text] [Related]  

  • 15. Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension.
    Mantero F; Armanini D; Urbani S
    Clin Sci Mol Med Suppl; 1973 Aug; 45 Suppl 1():219s-24. PubMed ID: 4522169
    [No Abstract]   [Full Text] [Related]  

  • 16. Spironolactone and triamterene in volume-dependent essential hypertension.
    DeCarvalho JG; Emery AC; Frohlich ED
    Clin Pharmacol Ther; 1980 Jan; 27(1):53-6. PubMed ID: 6985854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Spironolactone and thiabutazide in the treatment of essential hypertension (author's transl)].
    Klump F; Braun B; Klaus D; Lemke R; Zehner J; Zöfel P
    Dtsch Med Wochenschr; 1975 Mar; 100(12):577-84. PubMed ID: 1168122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.
    Vaughan ED; Laragh JH; Gavras I; Bühler FR; Gavras H; Brunner HR; Baer L
    Am J Cardiol; 1973 Sep; 32(4):523-32. PubMed ID: 4729722
    [No Abstract]   [Full Text] [Related]  

  • 19. Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension.
    Ferguson RK; Turek DM; Rovner DR
    Clin Pharmacol Ther; 1977 Jan; 21(1):62-9. PubMed ID: 318952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
    Ma J; Albornoz F; Yu C; Byrne DW; Vaughan DE; Brown NJ
    Hypertension; 2005 Aug; 46(2):313-20. PubMed ID: 15998706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.